Theravance Biopharma (TBPH) Misses Q2 EPS by 10c

Theravance Biopharma (NASDAQ: TBPH) reported Q2 EPS of ($0.11), $0.10 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $11.1 million versus the consensus estimate of $12.5 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• AXT appoints Tracy Liu to its board of directors
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins